Why the study?
Does dazoxiben 200 mg orally reduce Thromboxane B2 levels and improve haemodynamics during atrial pacing in patients with stable angina pectoris?
Does dazoxiben 200 mg orally reduce Thromboxane B2 levels and improve haemodynamics during atrial pacing in patients with stable angina pectoris?
Dazoxiben successfully inhibits pacing-induced thromboxane B2 release in patients with stable angina but does not translate to acute haemodynamic or metabolic benefits.
TXB2 suppression by dazoxiben yields no acute hemodynamic or metabolic benefit in stable angina; hypothesis-generating and should not change practice.
1 Thromboxane B2 (TXB2) levels were measured in three sites (coronary sinus, pulmonary artery, and femoral artery) at rest and during atrial pacing in 11 patients with stable angina pectoris. 2 There was a highly significant increase in arterial TXB2 on pacing (by up to 820 pg/ml) but there was no change in the thromboxane levels at the other two sites. 3 Dazoxiben 200 mg orally abolished the increase in arterial TXB2, but had no effect on systemic, pulmonary or coronary haemodynamics, no effect on myocardial metabolism and a variable effect on atrial pacing time to angina.
No takes yet. Share an insight, caveat, or question.
Kiff et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: